Article and Video CATEGORIES

Cancer Journey

Search By

Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Author
GRACE Videos and Articles

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

[powerpress]

Discuss this post in the GRACE Discussion Forums

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi James Anthony, I'm so sorry you are going through this and so very young.  It' s true that some people benefit for years with chemo and targeted therapies.  With the...

Hi siigs, I'm sorry you're having health issues. They don't sound like pancoast tumor symptoms.  A consult with a pulmonologist can help to understand your chest symptoms and work toward alleviating...

Hi Lonnie, 

Yes, the info in last year's OncTalk was up to date at that moment.  I think it would be well worth the watch along with videos in our 2025...

Recent Comments

JOIN THE CONVERSATION
ROS 1
By JanineT GRACE … on
Hi siigs, I'm sorry you're…
By JanineT GRACE … on
Tomorrow Saturday, Oct. 25, 2025
By JanineT GRACE … on
Blood Cancers OncTalk-Live, Free, Learn Sat. Oct. 25
By JanineT GRACE … on